Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
Stopped early · Phase 1
Conditions studied: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
In brief
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.
Key facts
- Study ID
- NCT03203369
- Run by
- Cellectis S.A.
- People needed
- 1
- Starts
- 2017-06-28
- Expected to finish
- 2019-06-27
- Last updated by the study team
- 2019-07-31
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.